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The live attenuated mycobacterial strain BCG, in use as vaccine against tuberculosis, is
considered the gold standard for primary therapy of carcinoma in situ of the bladder.
Despite its limitations, to date it has not been surpassed by any other treatment.
Our group has developed a recombinant BCG strain expressing the detoxified S1
pertussis toxin (rBCG-S1PT) that proved more effective than wild type BCG (WT-BCG)
in increasing survival time in an experimental mouse model of bladder cancer, due to the
well-known adjuvant properties of pertussis toxin. Here, we investigated the capacity
of rBCG-S1PT to stimulate human immune responses, in comparison to WT-BCG,
using an in vitro stimulation assay based on human whole blood cells that allows for
a comprehensive evaluation of leukocyte activation. Blood leukocytes stimulated with
rBCG-S1PT produced increased levels of IL-6, IL-8, and IL-10 as compared to WT-BCG,
but comparable levels of IL-1β, IL-2, IFN-γ, and TNF-α. Stimulation of blood cells with the
recombinant BCG strain also enhanced the expression of CD25 and CD69 on human
CD4+ T cells. PBMC stimulated with rBCG-S1PT induced higher cytotoxicity to MB49
bladder cancer cells than WT-BCG-stimulated PBMC. These results suggest that the
rBCG-S1PT strain is able to activate an immune response in human leukocytes that is
higher than that induced by WT-BCG for parameters linked to better prognosis in bladder
cancer (regulation of immune and early inflammatory responses), while fully comparable
to WT-BCG for classical inflammatory parameters. This establishes rBCG-S1PT as a new
highly effective candidate as immunotherapeutic agent against bladder cancer.
Keywords: recombinant BCG, bladder cancer, human immune cells, immunotherapy, adjuvant, CD4T cells,
cytokines
INTRODUCTION
The Bacille-Calmette-Guérin (BCG) is a live anti-tuberculosis vaccine, which has been
administered to more than 3 billion individuals worldwide over 80 years (1–3). BCG is also used
as immunotherapeutic treatment of non-muscle invasive bladder cancer (NMIBC). After over 40
years of use, BCG is still the gold standard for bladder cancer at early stage (4), by decreasing disease
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progression and the risk of recurrence (5). As mechanism of
anti-tumor activity, BCG instilled into the bladder induces a
local inflammatory immune response with influx of granulocytes
and mononuclear cells and a potent production of inflammatory
and Th1 cytokines, resulting in the activation of a significant
anti-tumor response (6, 7). However, BCG immunotherapy has
limitations, as ∼30% of patients do not respond to BCG, and
50% recur after BCG therapy (8, 9). In an attempt to increase
treatment efficacy, different strains of BCG have been used as
immunotherapy, as yet without satisfactory results (10, 11).
Several recombinant BCG (rBCG) strains have been
constructed as vaccine candidates for more efficient protection
against tuberculosis (12) and for new vaccines against viruses,
bacteria, and parasites (13, 14). Other rBCG strains have also
been constructed, expressing inflammatory or Th1 cytokines
such as IL-2, IL-12, IL-18, IFN-α, and IFN-γ, as potentially
improved immunotherapeutic tools for bladder cancer treatment
(15, 16). A rBCG strain expressing IFN-γ specifically increased
MHC class I molecules in the bladder cancer cell line MB49
in vitro and could prolong survival in mice with murine
orthotopic bladder cancer as compared to BCG treatment (17).
Another rBCG strain, which expresses IFN-α, induced increased
production of Th1 cytokines, and enhanced cytotoxicity by
peripheral blood mononuclear cells (PBMC) against bladder
cancer cell lines in vitro (18). Our group has constructed rBCG
strains expressing toxin derivatives (19, 20), including the
genetically detoxified S1 subunit of Pertussis Toxin-9K/129G
(S1PT) (21). The rBCG-S1PT strain was obtained from a
BCG Moreau background, the strain used in Brazil for both
TB vaccination and bladder cancer immunotherapy (22, 23).
Auxotrophic complementation allowed stable in vivo expression
of the S1PT protein, and the new strain induced a specific
cellular immune response that effectively protects neonate
mice from B. pertussis challenge (24). Based on the well-known
adjuvant properties of PT, i.e., its capacity to induce non-specific
immune/inflammatory activation, we have evaluated the rBCG-
S1PT strain for the immunotherapy of bladder cancer in a
murine model, in comparison with wild type BCG (WT-BCG).
That study demonstrated that the S1PT-expressing BCG strain
decreased more effectively bladder weight and induced a highly
significant increase in the survival of mice as compared with
WT-BCG (25, 26). As this recombinant BCG strain is being
prepared for evaluation in clinical trials as improved treatment
of bladder cancer, we are providing here data in support of its
improved immunotherapeutic performance by examining its
capacity to induce immune activation of human cells in vitro.
MATERIALS AND METHODS
Subjects and Blood Collection
Thirty-nine healthy adults (19 males and 20 females, aged 20–65
years) were recruited at the Hospital Universitário, Universidade
Abbreviations: BCG, Mycobacterium bovis Bacille Calmette-Guérin; NMIBC,
non-muscle invasive bladder cancer; PBMC, peripheral blood mononuclear cells;
PT, pertussis toxin; rBCG-S1PT, recombinant BCG expressing the detoxified PT S1
unit; WT-BCG, wild type BCG.
de São Paulo. Clinical history (obtained in a questionnaire)
and blood counts and serological parameters were used to
confirm the health conditions of the participants. Thirty-four
participants reported vaccination with live BCG at birth, while
five were not vaccinated. Ten milliliters of blood were collected
into heparinized tubes. The study protocol was approved
by the Comitê de Ética/Pesquisa Hospital Universitário/USP
(CEP-HU/USP) 728.275.
BCG Strains
The rBCG-S1PT strains were constructed based on a BCG
Moreau background (24). The BCG Moreau strain is one of
the early strains (together with BCG Russia and Japan) as
identified by genomic studies, while late strains include BCG
Pasteur and Danish (27). Several studies suggest that early BCG
vaccines may induce superior immune responses to the widely
used late strains (27). The strain used here is a complemented
auxotrophic recombinant BCG (24). The BCG Moreau strain
and rBCG-S1PT were grown in Middlebrook 7H9 medium with
albumin dextrose-catalase enrichment at 37◦C with 5% CO2
using stationary tissue culture flasks. Bacteria were harvested by
centrifugation, washed and stored in aliquots at−80◦C. Aliquots
were thawed and colony forming units (CFU) were determined
before use by plating onto Middlebrook 7H10 medium with oleic
albumin dextrose-catalase enrichment.
Whole Blood Assay
Whole blood stimulation (28) was performed by diluting 250
µL of fresh heparinized human whole blood (containing an
average of 1.8 × 106 nucleated cells) in 750 µL of RPMI-
1640 medium (GIBCO R©, Life Technologies, Paisley, UK) in
the presence of BCG or rBCG-S1PT (105 CFU/mL) in 1.5mL
polypropylene tubes. Thus, the multiplicity of infection (MOI)
obtained was approximately 0.1. Negative controls did not
contain mycobacteria. Positive controls received 2.5 ng/mL LPS
(from E. coli O55:B5; Sigma-Aldrich Inc., St. Louis, MO). Tubes
were tightly capped, mixed by inversion, and incubated at 37◦C
for 24 or 48 h. An aliquot of 100 µL was taken for cell staining
and phenotyping. The remaining cells in 0.9mL were lysed with
100 µL Triton-X (1% final concentration), and samples frozen at
−80◦C for cytokine measurement.
Cytokine Measurement
Frozen samples were thawed, centrifuged, and the supernatants
assayed for inflammation-related cytokines at 24 h (IL-1β,
IL-6, IL-8, IL-10, IL-12p70, TNF-α) and Th1/Th2/Th17-related
cytokines at 48 h (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, IL-17A)
with Cytometric Bead Array kits (CBA; BD Biosciences, San
Jose, CA), as per the manufacturer’s instructions. The assays’
lower limits of detection were between 2.6 and 18.9 pg/mL,
depending on the cytokine, and the higher limit was 5,000
pg/mL. All samples were tested undiluted and, if values were
above threshold, were diluted and retested. Samples below
the lower threshold limit were considered as zero. Testing
of some cytokines at both time points demonstrated that the
majority/totality of production occurred within the first 24 h
(Supplementary Figure 1). Values are expressed as pg or ng
cytokines/mL of blood.
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Cell Phenotypic Analysis
Phenotypic analysis was performed after 48 h. Cells were treated
with 2µM EDTA (Sigma Aldrich Inc.) for 10min and washed
with PBS, then incubated for 30min at room temperature with
the following conjugated mAbs: CD3-APC-H7, CD4-PECy-5,
CD25-BV510, and CD69-FITC. After incubation, red blood
cells were lysed using 2mL FACS lysing solution, and flow
cytometric acquisition was performed with a FACS Canto II after
optimization of settings using the cytometer setup and tracking
beads. Instrument and reagents were from BD Bioscience. Data
were analyzed using FlowJo version 7.6.5. No differences in the
proportion of dead cells were evident between treatments and
between treatments and controls, by scattering analysis.
Cytotoxicity Assay
MB49-GFP cells (mouse bladder carcinoma cell line MB49 cells
modified to constitutively express green fluorescent protein,
GFP) were maintained in RPMI-1640 medium containing 10%
heat-inactivated fetal bovine serum at 37◦C in humidified air
with 5% CO2 (25). The MB49-GFP cells were detached by
trypsin treatment, seeded in 96-well flat-bottom microplates at
3.5 × 104 cell/well, and incubated for 24 h until confluent.
Human PBMC were isolated from heparinized blood samples
with standard procedures using Ficoll-Paque (GE Healthcare
Bio-Science AB, Uppsala, Sweden). PBMC were mixed with
WT-BCG or rBCG-S1PT at MOI 0.1 and immediately added
to MB49-GFP cell cultures at the initial PBMC to tumor cell
ratios of 12.5:1, 25:1 and 50:1. After an overnight incubation, the
plates were washed with sterile PBS twice, the MB49-GFP cells
were detached by trypsinization (50 µL/well, 4min), collected
by centrifugation, resuspended in 50 µL/well of ice-cold RPMI-
1640 and counted in a hemacytometer with a fluorescence
microscope (Nikon E200).
Percent cytotoxicity (which in this assay measures the sum of
cytolytic and cytostatic effects) was expressed by taking as 0 the
number of tumor cells in the absence of PBMC and BCG, and
100% the absence of tumor cells. Neither WT-BCG not rBCG-
S1PT at the concentrations used had a direct cytotoxic effect on
tumor cells.
Statistical Analysis
Statistical analysis was performed with the GraphPad Prism
6.02 software package (GraphPad software, San Diego, CA,
USA). Analysis on cytokine levels and cell phenotypes were
performed using a one-way analysis of variance (ANOVA) with a
Bonferroni’s multiple-comparison test, and the cytotoxicity assay
using Student’s t-test. Differences between groups with p ≤ 0.05
were considered significant.
RESULTS
rBCG-S1PT Induces Cytokine Production
in Human Blood Cells
Preliminary experiments were run for selecting the WT-BCG
and rBCG-S1PT MOI to use in the study. Based on literature
data suggesting a MOI of 0.1 as optimal (29), we set up dose-
response experiments with three donors (two vaccinated with
FIGURE 1 | Dose-response of WT-BCG and rBCG-S1PT in activating cytokine
production by human blood cells in vitro. Blood cells from three individual
donors (Donors 1 and 2 had been vaccinated with BCG, Donor 3 was
non-vaccinated) were exposed for 24 h to increasing MOI of WT-BCG or
rBCG-S1PT. Cytokines were measured with a CBA assay and expressed as
cytokine concentration /mL blood. Spontaneous release by non-stimulated
cells was subtracted. This was 0.8–1.6 ng/mL for IL-8, 24–92 pg/mL for IL-1β,
and 20–89 pg/mL for IL-6.
BCG and one non-vaccinated), in which we compared the ability
of WT-BCG and rBCG-S1PT to induce cytokine production
by using a rapid and very efficient assay on whole blood,
which assesses the global response of blood cells to exogenous
stimuli (28). Cytokines assessed were the chemokine IL-8 and
the inflammatory cytokines IL-1β and IL-6. MOI used were
0.1 and below, in an attempt to identify differences between
the two BCG types in the perspective of dose reduction in
future therapeutic approaches. The results in Figure 1 show that
for both BCG strains the MOI 0.1 was the concentration that
stimulated a substantial reaction in all donors. The response to
rBCG-S1PT was higher than that to WT-BCG at this MOI and,
for Donor 2 (all cytokines) and Donor 3 (IL-8), also at MOI 0.01.
Minimal or no reaction was observed at MOI 0.001 for either
BCG strain.
Once chosen the MOI, we have tested the human response
to BCG strains more extensively, using the same assay on
whole blood cells. Since effector cells in a localized tissue
inflammation are recruited from blood, assessing human blood
cell reaction to BCG is a relevant way to evaluate local
immune/inflammatory reactivity. Human blood from healthy
donors was exposed in vitro to WT-BCG or rBCG-S1PT, and
immune reactivity assessed after 24 and 48 h. The results
reported in Figure 2 show that rBCG-S1PT induces a similar
cytokine profile as WT-BCG, i.e., significant production of
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FIGURE 2 | Production of cytokines by blood cells from healthy adults stimulated with WT-BCG or rBCG-S1PT. Blood cells were stimulated with WT-BCG or
rBCG-S1PT and cytokines were measured with a CBA array. Data at 24 h are reported for the early inflammation-related cytokines IL-8 (A), IL-1β (B), IL-6 (C), and
TNF-α (D), while results at 48 h are shown for the T-related cytokines IL-10 (E), IL-2 (F), IFN-γ (G), and IL-17A (H). Values represent the concentration of cytokines per
mL blood. Negative controls are non-stimulated cells. Positive controls (cells stimulated with LPS) were: IL-8, 133.40 ± 13.63 ng/mL; IL-1β, 13.45 ± 1.28 ng/mL;
IL-6, 80.11 ± 12.30 ng/mL; TNF-α, 0.16 ± 0.04 ng/mL; IL-10, 95.04 ± 17.61 pg/mL; IL-2, 3.58 ± 0.83 pg/mL; IFN-γ, 798.21 ± 187.08 pg/mL; and IL-17, 1004.74
± 143.52 pg/mL. ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05 vs. negative controls. The p value for the difference between BCG groups is indicated over
the bar.
IL-8, IL-1β, IL-6, TNF-α, IL-10, and IL-2. For IFN-γ, only
production induced by WT-BCG reached statistical significance,
while that induced by rBCG-S1PT showed a tendency to increase
that was not significant (p = 0.06) by ANOVA, although it
was significant by the Student’s t test (not shown). There
was no significant production of IL-4 or IL-12 in response
to either BCG strain (not shown), while IL-17 was produced
constitutively and was not increased upon stimulation with
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FIGURE 3 | CD4+ T cell activation in blood cells from healthy adults stimulated with WT-BCG or rBCG-S1PT. Blood cells were stimulated with WT-BCG or
rBCG-S1PT for 48 h and analyzed phenotypically by flow cytometry. (A) gating strategy; (B) percentage of CD4+/CD25+ cells; (C) percentage of CD4+/CD69+ cells;
(D) percentage of CD4+/CD69+/CD25+ cells. Negative controls are non-stimulated cells. ****p < 0.0005, ***p < 0.001, and **p < 0.01 vs. negative controls.
BCG (Figure 2H). Notably, rBCG-S1PT was able to stimulate
a significantly higher production of IL-8, IL-6, and IL-10 when
compared to WT-BCG (Figures 2A,C,E). While production of
inflammatory cytokines (IL-8, IL-1β) was generally examined
at 24 h, and that of T-related cytokines (IL-2, IFN-γ, IL-
17) at 48 h, the production of IL-6, TNF-α, and IL-10 was
evaluated at both 24 and 48 h (Supplementary Figure 1). The
cytokine profiles (including differences between recombinant
and wild type BCG) were comparable between the two time
points, although their level was lower at 48 h. This suggests
that for these cytokines the production mainly occurred in the
first 24 h.
By examining data in Figures 1, 2, a great variability in
the individual response to BCG can be observed both in the
amount of cytokine produced and reactivity to the different
strains. Indeed, the response to BCG varies substantially
among donors. As an example, IL-8 production goes from
20 to 4,000 pg/mL blood in response to MOI 0.1 rBCG-
S1PT in 24 h. It is also clear that individual donors can be
differently sensitive to the enhanced effect of rBCG-S1PT, as
for instance in the case of the superior IL-1β induction shown
in Figure 1, while this effect was not evident when examining
a larger cohort (Figure 2B). This would suggest the need of
personalized testing for patients undergoing BCG therapy for
bladder cancer.
The results shown in Figure 2 were obtained with blood
cells from 34 donors that were vaccinated with BCG at birth.
In order to examine whether the differential responsiveness to
rBCG-S1PT vs. WT-BCG depended on previous vaccination the
response to BCG was assessed in a very limited group of non-
vaccinated donors (n= 5), for the reason that BCG vaccination is
compulsory in Brazil since 1967 and non-vaccinated individuals
are rare. The results in Supplementary Figure 2 show that non-
vaccinated donors also respond to rBCG-S1PT with a higher
production of IL-8, IL-6, and IL-10, as shown for vaccinated
donors. Notably, the absolute activation level is about 5–10-
fold lower in non-vaccinated donors (both for BCG strains and
for LPS), but the activation induced by rBCG-S1PT reaches a
level that is within the same range of the response of vaccinated
donors to WT-BCG (IL-8: 200–380 ng/ml with rBCG-S1PT
in non-vaccinated donors vs. 50–3,000 ng/ml with WT-BCG
in vaccinated donors; IL-6: 0–48 ng/ml with rBCG-S1PT in
non-vaccinated vs. 0–190 ng/ml with WT-BCG in vaccinated
donors; IL-10: 20–180 pg/ml with rBCG-S1PT in non-vaccinated
donors vs. 0–200 pg/ml with WT-BCG in vaccinated donors)
(Supplementary Figure 2).
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rBCG-S1PT Induces Activation of Human
Blood CD4+ T Cells
To investigate whether rBCG-S1PT is able to activate T
cells, we examined the expression of CD25 and CD69 on
human blood CD4+ T cells upon exposure to rBCG-S1PT,
in comparison to WT-BCG. Figure 3A shows the gating
strategy for cytofluorimetric marker detection. Both BCG strains
significantly enhanced the expression of CD25 molecules on
CD4+ T cells (Figure 3B), implying a comparable capacity
to activate CD4+ T cells. We also evaluated the expression
of the early activation marker CD69. Both WT-BCG and
rBCG-S1PT could enhance CD69 expression on CD4+ T
cells, although rBCG-S1PT was not as efficient as WT-
BCG (Figure 3C). When assessing the number of CD4+
T cells co-expressing CD25 and CD69, both BCG strains
efficiently and comparably enhanced the number of activated
cells (Figure 3D).
rBCG-S1PT Stimulation of Human Blood
Cells Induces Tumor Cytotoxicity
To investigate whether rBCG-S1PT can activate the anti-tumor
activity of human leukocytes, we have set up an in vitro
assay that measures the global cytotoxic effect, comprising
both cytolysis (cell death) and cytostasis (block/decrease of cell
proliferation). The assay is based on the assessment of the
number of living tumor cells present in culture after incubation
with effector leukocytes. To mimic in vivo conditions, leukocytes
were co-cultured with cells from a bladder cancer cell line
in the presence of BCG. In the conditions used, BCG had
no direct cytotoxic effect on tumor cells (not shown). As
shown in Figure 4, PBMC of three different donors showed a
measurable spontaneous cytotoxic effect for tumor cells, which
was significantly increased by both WT-BCG and rBCG-S1PT
(Figure 4A). For each donor, the effect of recombinant BCG
was higher than that induced by the wild type strain and is
particularly evident at the effector to target ratio of 12.5:1
(Figure 4B). At higher effector to target ratios (25:1, 50:1) the
cytotoxicity was nearly 100% for all donors with both BCG
strains (Figure 4A).
DISCUSSION
Weprovide evidence that rBCG-S1PT is efficient in the activation
of human CD4+ lymphocytes and of innate/inflammatory
immune response, the latter being superior to that induced
by WT-BCG, likely relying on the potent non-specific
adjuvant capacity of the expressed detoxified S1PT (20).
Previous data showing the improved performance of
rBCG-S1PT in a mouse model of bladder cancer (25, 26)
are supported by data in this study, showing a peculiar
activation profile induced by the recombinant strain that is
suggestive of a more effective initiation and regulation of
immune reactivity.
Our results show that stimulation of human blood cells in
vitrowith both rBCG-S1PT andWT-BCG induce the production
FIGURE 4 | Tumor cytotoxicity of human blood mononuclear cells activated
with WT-BCG or rBCG-S1PT. (A) Blood mononuclear cells were incubated for
24 h with MB49-GFP bladder tumor cells at different effector to target ratios
(12.5:1, 25:1, 50:1) in the absence or in the presence of WT-BCG or
rBCG-S1PT at MOI 0.1. Tumor cytotoxicity was assessed as % reduction of
cell number vs. control cells incubated without PBMC and without BCG and
expressed as mean ± SEM of three donors. (B) Data from 3 individual donors
are presented at the effector to target ratio of 12.5:1, two that were vaccinated
with BCG (1 and 3) and one that was not vaccinated (2). Statistical significance
was assessed by Student’s t-test. ϕp < 0.05, WT-BCG vs. control PBMC;
#p < 0.05, rBCG-S1PT vs. control PBMC; *p < 0.05, rBCG-S1PT vs.
WT-BCG. In panel B, the p value for the difference between BCG groups is
indicated over the bar.
of inflammatory cytokines, essential for the induction of non-
specific innate immune activation, within 24 h. While levels
of the classical inflammatory cytokines IL-1β and TNF-α are
enhanced in a comparable fashion by both strains, production
of IL-8 and IL-6 is significantly higher in rBCG-S1PT-stimulated
cells. Urinary levels of IL-8, IL-6, and also IL-10, are important
markers to evaluate the efficacy of BCG instillations in the
treatment of NMIBC (30). Urinary IL-8 has been considered a
potential prognostic factor for tumor recurrence and progression
following BCG therapy (31), while decreased IL-6 serum levels
in patients with bladder cancer correlate with the appearance
of myeloid-derived suppressor cells and poor prognosis (32).
The capacity of PT to induce IL-6 production in mice (33, 34)
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may explain the finding that human blood cells produce higher
IL-6 levels when stimulated with rBCG-S1PT in comparison
to WT-BCG.
In the murine bladder cancer model, treatment with rBCG-
S1PT induced an increase in IL-10 mRNA and in the survival
time of the animals (25). Here we demonstrated that rBCG-S1PT
induces a significantly higher production of IL-10, in parallel
to the favorable markers IL-8 and IL-6, as compared to WT-
BCG, also in human blood leukocytes. The higher production
of IL-10 induced by rBCG-S1PT as compared to WT-BCG
reveals a tighter control of the Th1-dependent inflammatory
response, which may result in an effective induction of response
in the absence of significant inflammatory side effects. Thus, the
enhanced IL-10 production should be considered as amechanism
of protection against tissue injury and pathological processes
associated with Th1 and inflammatory cytokines (35, 36).
The overproduction of IL-6 and IL-8 in combination with
increased IL-10 and stable production of IL-1β and TNF-α
suggests that rBCG-S1PT establishes an efficient compensatory
mechanism to control excessive inflammation.
IFN-γ production was induced by both BCG strains in about
one third of donors, while all others were unreactive. This is
similar to the production of TNF-α, and suggests a significant
heterogeneity in individual responsiveness to BCG, relative to
these key inflammatory cytokines, which may imply different
outcomes in terms of therapeutic efficacy. Other cytokines
such as IL-2 and IL-17 were not significantly induced by
either BCG strain. IL-17 was measurably produced by non-
stimulated blood cells in about two thirds of the donors, and
exposure to BCG did not increase its production nor the number
of cytokine-producing donors. Also in the case of IL-2, two
subpopulations of donors, responders and non-responders, could
be identified. It is notable that in the case of IL-2 the vast
majority of donors was able to respond to rBCG-S1PT, while
only two thirds of donors could respond to WT-BCG. The
Th-related cytokines IL-12 and IL-4 were not produced in
response to either BCG strain, suggesting that the major effects
of BCG are on innate immunity and inflammatory responses,
without a significant direct effect on the later stages of adaptive
immune response.
Immunological evaluation of patients with NMIBC show
that BCG treatment induces predominantly CD4+ activation
(7). Indeed, in vitro exposure of human blood cells to BCG
strains induces activation of CD4+ T cells. Our results show
that in vitro stimulation of blood cells induced an increase
in the number of CD4+/CD25+ T cells, which is comparable
between WT-BCG and rBCG-S1PT. This is in agreement with
previous findings that show induction of CD25 (IL-2Rα, a marker
of T cell activation) on lymphocytes following infection with
mycobacteria in vivo and in vitro (37, 38). Stimulation of blood
cells with rBCG-S1PT or WT-BCG also induced a significant
increase in the early activation marker CD69 in CD4+ T cells,
an increase that has been correlated with immune sensitization
to mycobacterial antigens (39). In the present study, both WT-
BCG and rBCG-S1PT induced CD69 expression on blood CD4+
T cells. The higher increase induced byWT-BCG suggests a more
pronounced early activation. However, fully activated CD4+ T
cells co-expressing CD25 and CD69 were equally induced by
rBCG-S1PT and WT-BCG, implying an essentially similar T cell
activation profile.
Enhanced IL-8 and IL-6 production in response to rBCG-
S1PT implies improved recruitment and stimulation of blood-
derived immune cells. On the other hand, it is notable that
there is no significant difference in the induction of IL-1β and
TNF-α, both endowed with potent inflammatory properties but
important for immune stimulation. The stable production of
these two factors suggests that, while immune stimulation is
maintained at the same level as with WT-BCG, rBCG-S1PT does
not increase detrimental inflammatory effects.
It has been shown that BCG-stimulated PBMCs induce death
of tumor cell lines through a complex mechanism involving the
activation of macrophages and CD4+ T cells, which leads to the
generation of BCG-activated killer cells (BAK cells - CD8+ T
cells) stimulated by IL-2 and IFN-γ (40). We investigated the
ability of rBCG-S1PT to activate the direct cytotoxic activity
of human leukocytes against tumor cells in vitro. Notably,
while both WT-BCG and rBCG-S1PT significantly increased the
cytotoxic capacity of leukocytes, the recombinant strain induced
a higher effect on cells from all the tested donors. It will be
important to further investigate the relative role of lymphocytes
and monocytes (which also get potently activated by BCG in
vitro; data not shown) in the cytotoxicity against MB49 cells.
Our study was mainly run with blood samples taken from
BCG-vaccinated volunteers. It is interesting to note that, in
a limited number of non-immunized donors, reactivity to the
two BCG strains displayed the same profile as that described
here for immunized donors, although the absolute levels of
cytokines were lower. Indeed, there are suggestions in the
literature that BCG vaccination may improve the efficacy of BCG
immunotherapy in bladder cancer therapy, both in experimental
models and in human patients (41). A pilot study is currently
ongoing to assess the effect of BCG vaccination in bladder cancer
patients (42).
Based on the data described here, we can conclude that
human blood cells challenged with rBCG-S1PT in a realistic
in vitro model show an improved immune activation profile
in comparison to WT-BCG, in terms of cytokine production
and tumor cytotoxicity. This evidence strengthens the results
of improved bladder cancer treatment in a mouse model
(25) and indicate rBCG-S1PT as an excellent candidate
for a more effective immunotherapy of non-muscle-invasive
bladder cancer.
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Supplementary Figure 1 | Time-dependent production of cytokines by blood
cells from healthy adults stimulated with WT-BCG or rBCG-S1PT. Blood cells were
stimulated with WT-BCG or rBCG-S1PT and cytokines were measured with a
CBA array at 24 and 48 h. Values represent the concentration of cytokines per mL
blood. Negative controls are non-stimulated cells. Positive controls (cells
stimulated with LPS) were: IL-6, 45.53 ± 8.40 ng/mL; TNF-α, 0.10 ± 0.01 ng/mL;
IL-10, 123.56 ± 33.38 pg/mL. ∗∗∗∗p < 0.0005, ∗∗∗p < 0.001, ∗∗p < 0.01,
∗p < 0.05 vs. negative controls.
Supplementary Figure 2 | Production of cytokines by blood cells from
non-vaccinated and BCG-vaccinated healthy adults stimulated with WT-BCG or
rBCG-S1PT. Blood cells from non-vaccinated donors (left panels) or donors
vaccinated with BCG (right panels, same as in Figure 2 and
Supplementary Figure 1) were stimulated with WT-BCG or rBCG-S1PT for 24 h.
Cytokines were measured with a CBA array and expressed as concentration per
mL blood. Negative controls are non-stimulated cells. Positive controls (cells
stimulated with LPS) were: for non-vaccinated donors, IL-8, 46.86 ± 4.26 ng/mL;
IL-6, 36.22 ± 8.10 ng/mL; IL-10, 8.72 ± 0.63 pg/mL; for vaccinated donors, IL-8,
133.40 ± 13.63 ng/mL; IL-6, 80.11 ± 12.30 ng/mL; IL-10, 95.04 ± 17.61 pg/mL;
∗∗∗∗p < 0.0005, ∗∗∗p < 0.001, and ∗∗p < 0.01 vs. negative control or
WT-BCG groups.
REFERENCES
1. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines
against tubérculosis. In: BloomB, editor.Tuberculosis: Pathogenesis, Protection
and Control. Washington, DC: American Society for Microbiology Press
(1994). p. 531–57. doi: 10.1128/9781555818357.ch31
2. WHO. BCG Vaccines: WHO Position Paper - February 2018. Weekly
epidemiological record, No 8, 2018, 93, 73–96. Available online at: https://
apps.who.int/iris/bitstream/handle/10665/260306/WER9308.pdf;jsessionid=
80E566859F34C3F976C21703C82DF433?sequence=1
3. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint
for the next decade. Tuberculosis. (2012) 92(Suppl. 1):S6–13.
doi: 10.1016/S1472-9792(12)70005-7
4. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder
cancer: an immunotherapy success story. J Urol. (2008) 179:53–6.
doi: 10.1016/j.juro.2007.08.122
5. Maruf M, Brancato SJ, Agarwal PK. Non-muscle invasive bladder cancer:
a primer on immunotherapy. Cancer Biol Med. (2016) 13:194–205.
doi: 10.20892/j.issn.2095-3941.2016.0020
6. Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy
and its outlook for bladder cancer. Nat Rev Urol. (2018) 15:615–25.
doi: 10.1038/s41585-018-0055-4
7. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin
immunotherapy for superficial bladder cancer. J Urol. (2003) 170:964–9.
doi: 10.1097/01.ju.0000073852.24341.4a
8. Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscle-
invasive bladder cancer: a critical analysis of currently available drugs,
treatment schedules, and long-term results. Eur Urol. (2008) 53:45–52.
doi: 10.1016/j.eururo.2007.08.015
9. Punnen SP, Chin JL, Jewett MA. Management of bacillus Calmette-Guerin
(BCG) refractory superficial bladder cancer: results with intravesical BCG and
Interferon combination therapy. Can J Urol. (2003) 10:1790–5.
10. Sengiku A, Ito M, Miyazaki Y, Sawazaki H, Takahashi T, Ogura
K. A prospective comparative study of intravesical bacillus Calmette-
Guerin therapy with the Tokyo or Connaught strain for non-muscle
invasive bladder cancer. J Urol. (2013) 190:50–4. doi: 10.1016/j.juro.2013.
01.084
11. Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, et al. The
efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with
T1G3 non-muscle-invasive bladder cancer. Urol Oncol. (2016) 34:484 e19–25.
doi: 10.1016/j.urolonc.2016.05.033
12. Nieuwenhuizen NE, Kaufmann SHE. Next-generation vaccines
based on bacille Calmette-Guerin. Front Immunol. (2018) 9:121.
doi: 10.3389/fimmu.2018.00121
13. Aldovini A, Young RA. Humoral and cell-mediated immune responses
to live recombinant BCG-HIV vaccines. Nature. (1991) 351:479–82.
doi: 10.1038/351479a0
14. Ohara N, Yamada T. Recombinant BCG vaccines.Vaccine. (2001) 19:4089–98.
doi: 10.1016/S0264-410X(01)00155-4
15. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of
antimycobacterial immunity using recombinant bacille Calmette-Guerin
strains that secrete cytokines. Proc Natl Acad Sci USA. (1996) 93:934–9.
doi: 10.1073/pnas.93.2.934
16. Wang Y, Yang M, Yu Q, Yu L, Shao S, Wang X. Recombinant
bacillus Calmette-Guerin in urothelial bladder cancer immunotherapy:
current strategies. Expert Rev Anticancer Ther. (2015) 15:85–93.
doi: 10.1586/14737140.2015.961430
17. Arnold J, de Boer EC, O’Donnell MA, Bohle A, Brandau S.
Immunotherapy of experimental bladder cancer with recombinant
BCG expressing interferon-gamma. J Immunother. (2004) 27:116–23.
doi: 10.1097/00002371-200403000-00005
18. Liu W, O’Donnell MA, Chen X, Han R, Luo Y. Recombinant bacillus
Calmette-Guerin (BCG) expressing interferon-alpha 2B enhances human
mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer
Immunol Immunother. (2009) 58:1647–55. doi: 10.1007/s00262-009-0673-z
19. Mazzantini RP, Miyaji EN, Dias WO, Sakauchi D, Nascimento AL, Raw I,
et al. Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on
the immune response induced by BCG expressing tetanus toxin fragment C.
Vaccine. (2004) 22:740–6. doi: 10.1016/j.vaccine.2003.08.017
20. Nascimento IP, Dias WO, Mazzantini RP, Miyaji EN, Gamberini M, Quintilio
W, et al. Recombinant Mycobacterium bovis BCG expressing pertussis
toxin subunit S1 induces protection against an intracerebral challenge
with live Bordetella pertussis in mice. Infect Immun. (2000) 68:4877–83.
doi: 10.1128/IAI.68.9.4877-4883.2000
Frontiers in Immunology | www.frontiersin.org 8 June 2019 | Volume 10 | Article 1460
Rodriguez et al. Recombinant BCG Activates Human Immunity
21. Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, DeMagistris MT, et
al. Mutants of pertussis toxin suitable for vaccine development. Science. (1989)
246:497–500. doi: 10.1126/science.2683073
22. Benevolo-de-Andrade TC, Monteiro-Maia R, Cosgrove C, Castello-
Branco LR. BCG Moreau Rio de Janeiro: an oral vaccine against
tuberculosis–review. Mem Inst Oswaldo Cruz. (2005) 100:459–65.
doi: 10.1590/S0074-02762005000500002
23. Hofbauer SL, Shariat SF, Chade DC, Sarkis AS, Ribeiro-Filho LA, Nahas
WC, et al. The moreau strain of bacillus Calmette-Guerin (BCG) for
high-risk non-muscle invasive bladder cancer: an alternative during
worldwide BCG shortage? Urol Int. (2016) 96:46–50. doi: 10.1159/0004
40701
24. Nascimento IP, Dias WO, Quintilio W, Hsu T, Jacobs WR Jr., Leite
LC. Construction of an unmarked recombinant BCG expressing a
pertussis antigen by auxotrophic complementation: protection against
Bordetella pertussis challenge in neonates. Vaccine. (2009) 27:7346–51.
doi: 10.1016/j.vaccine.2009.09.043
25. Andrade PM, Chade DC, Borra RC, Nascimento IP, Villanova FE, Leite LC, et
al. The therapeutic potential of recombinant BCG expressing the antigen S1PT
in the intravesical treatment of bladder cancer. Urol Oncol. (2010) 28:520–5.
doi: 10.1016/j.urolonc.2008.12.017
26. Chade DC, Borra RC, Nascimento IP, Villanova FE, Leite LC, Andrade E, et al.
Immunomodulatory effects of recombinant BCG expressing pertussis toxin
on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res.
(2008) 27:78. doi: 10.1186/1756-9966-27-78
27. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, et al.
Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci
USA. (2007) 104:5596–601. doi: 10.1073/pnas.0700869104
28. Puren AJ, Razeghi P, Fantuzzi G, Dinarello CA. Interleukin-18 enhances
lipopolysaccharide-induced interferon-gamma production in human
whole blood cultures. J Infect Dis. (1998) 178:1830–4. doi: 10.1086/
314481
29. Chavez-Galan L, Vesin D, Martinvalet D, Garcia I. Low dose BCG infection as
a model for macrophage activation maintaining cell viability. J Immunol Res.
(2016) 2016:4048235. doi: 10.1155/2016/4048235
30. Klap J, Schmid M, Loughlin KR. Biomarkers in patients treated with BCG: an
update. Can J Urol. (2014) 21:7335–43.
31. Thalmann GN, Dewald B, Baggiolini M, Studer UE. Interleukin-8 expression
in the urine after bacillus Calmette-Guerin therapy: a potential prognostic
factor of tumor recurrence and progression. J Urol. (1997) 158:1340–4.
doi: 10.1016/S0022-5347(01)64210-1
32. Yang G, Shen W, Zhang Y, Liu M, Zhang L, Liu Q, et al. Accumulation
of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6
correlates with poor prognosis in bladder cancer.Oncotarget. (2017) 8:38378–
88. doi: 10.18632/oncotarget.16386
33. Dumas A, Amiable N, de Rivero Vaccari JP, Chae JJ, Keane RW,
Lacroix S, et al. The inflammasome pyrin contributes to pertussis
toxin-induced IL-1beta synthesis, neutrophil intravascular crawling,
and autoimmune encephalomyelitis. PLoS Pathog. (2014) 10:e1004150.
doi: 10.1371/journal.ppat.1004150
34. Richard JF, Roy M, Audoy-Remus J, Tremblay P, Vallieres L. Crawling
phagocytes recruited in the brain vasculature after pertussis toxin exposure
through IL6, ICAM1, and ITGalphaM. Brain Pathol. (2011) 21:661–71.
doi: 10.1111/j.1750-3639.2011.00490.x
35. da Silva MV, Figueiredo AA, Machado JR, Castellano LC, Alexandre
PB, Oliveira RF, et al. T cell activation and proinflammatory cytokine
production in clinically cured tuberculosis are time-dependent and
accompanied by upregulation of IL-10. PLoS ONE. (2013) 8:e65492.
doi: 10.1371/journal.pone.0065492
36. Ponte C, Peres L, Marinho S, Lima J, Siqueira M, Pedro T, et al. In vitro T-cell
profile induced by BCG Moreau in healthy Brazilian volunteers. Hum Vaccin
Immunother. (2015) 11:450–7. doi: 10.4161/21645515.2014.970954
37. Storset AK, Berntsen G, Larsen HJ. Kinetics of IL-2 receptor expression
on lymphocyte subsets from goats infected with Mycobacterium avium
subsp. paratuberculosis after specific in vitro stimulation. Vet Immunol
Immunopathol. (2000) 77:43–54. doi: 10.1016/S0165-2427(00)00227-0
38. Whist SK, Storset AK, Larsen HJ. The use of interleukin-2 receptor expression
as a marker of cell-mediated immunity in goats experimentally infected with
Mycobacterium avium ssp. paratuberculosis. Vet Immunol Immunopathol.
(2000) 73:207–18. doi: 10.1016/S0165-2427(00)00155-0
39. Avgustin B, Kotnik V, Skoberne M, Malovrh T, Skralovnik-Stern A,
Tercelj M. CD69 expression on CD4+ T lymphocytes after in vitro
stimulation with tuberculin is an indicator of immune sensitization against
Mycobacterium tuberculosis antigens. Clin Diagn Lab Immunol. (2005)
12:101–6. doi: 10.1128/CDLI.12.1.101-106.2005
40. Brandau S, Bohle A, Thanhauser A, Ernst M, Mattern T, Ulmer AJ, et al. In
vitro generation of bacillus Calmette-Guerin-activated killer cells. Clin Infect
Dis. (2000) 31:S94–100. doi: 10.1086/314068
41. Biot C, Rentsch CA, Gsponer JR, Birkhauser FD, Jusforgues-Saklani H,
Lemaitre F, et al. Preexisting BCG-specific T cells improve intravesical
immunotherapy for bladder cancer. Sci Transl Med. (2012) 4:137ra72.
doi: 10.1126/scitranslmed.3003586
42. Nykopp TK, Batista da Costa J, Mannas M, Black PC. Current clinical
trials in non-muscle invasive bladder cancer. Curr Urol Rep. (2018) 19:101.
doi: 10.1007/s11934-018-0852-6
Conflict of Interest Statement: LL and IN have a patent application on the use of
rBCG-S1PT in bladder cancer treatment.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Rodriguez, Goulart, Pagliarone, Silva, Cunegundes, Nascimento,
Borra, Dias, Tagliabue, Boraschi and Leite. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 9 June 2019 | Volume 10 | Article 1460
